Recalls

All US Product Recalls

Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.

How to read this listing

Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.

The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.

Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.

Agency

All agencies FDA (Food)FDA (Drugs)FDA (Devices)USDA FSIS CPSC NHTSA EPA

9176–9200 of 11823

SevereFDA (Drugs)·D-713-2015·2015-04-29
Attix Pharmaceuticals Recalls Hydrocortisone Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling hydrocortisone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Hydrocortisone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-671-2015·2015-04-29
Famciclovir Recalled Due to Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling famciclovir active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Famciclovir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-662-2015·2015-04-29
Attix Pharmaceuticals Recalls Ethopropazine HCI Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Ethopropazine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Ethopropazine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-626-2015·2015-04-29
Attix Pharmaceuticals Recalls Dexmedetomidine HCI Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Dexmedetomidine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.
Product
Dexmedetomidine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-547-2015·2015-04-29
Attix Pharmaceuticals Recalls Bromfenac Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Bromfenac Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Bromfenac Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-597-2015·2015-04-29
Attix Pharmaceuticals Recalls Clopidogrel Bisulfate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Clopidogrel Bisulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Clopidogrel Bisulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-726-2015·2015-04-29
Attix Pharmaceuticals Recalls Hyoscyamine Sulfate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hyoscyamine Sulfate Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Hyoscyamine Sulfate Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-725-2015·2015-04-29
Attix Pharmaceuticals Recalls Hyoscine Butylbromide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hyoscine Butylbromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Hyoscine Butylbromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-643-2015·2015-04-29
Attix Pharmaceuticals Recalls Doxycycline Monohydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Doxycycline Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Doxycycline Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-750-2015·2015-04-29
Leflunomide API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Leflunomide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Leflunomide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-589-2015·2015-04-29
Attix Pharmaceuticals Recalls Cisatracurium Besylate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cisatracurium Besylate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Cisatracurium Besylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-901-2015·2015-04-29
Attix Pharmaceuticals Recalls Sodium Starch Glycolate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Sodium Starch Glycolate pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Sodium Starch Glycolate pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-580-2015·2015-04-29
Attix Pharmaceuticals Recalls Chloroxine Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Chloroxine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Chloroxine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-678-2015·2015-04-29
Attix Pharmaceuticals Recalls Flucytosine Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Flucytosine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Flucytosine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-715-2015·2015-04-29
Attix Pharmaceuticals Recalls Hydrocortisone Micronized Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hydrocortisone Micronized active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Hydrocortisone Micronized active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-885-2015·2015-04-29
Attix Pharmaceuticals Recalls Ropivacaine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Ropivacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Ropivacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-842-2015·2015-04-29
Attix Pharmaceuticals Recalls Pimecrolimus Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Pimecrolimus active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Pimecrolimus active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-763-2015·2015-04-29
Lincomycin HCl Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Lincomycin HCl Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.
Product
Lincomycin HCl Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-667-2015·2015-04-29
Attix Pharmaceuticals Recalls Etravirine API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Etravirine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Etravirine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-921-2015·2015-04-29
Terbinafine HCl Recalled for Potential Penicillin Cross-Contamination
Attix Pharmaceuticals is recalling Terbinafine HCl active pharmaceutical ingredient due to potential cross-contamination with penicillin during repackaging.
Product
Terbinafine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-526-2015·2015-04-29
Atazanavir API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Atazanavir active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Atazanavir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-798-2015·2015-04-29
Miltefosine API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Miltefosine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Miltefosine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-562-2015·2015-04-29
Attix Pharmaceuticals Recalls Carboplatin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Carboplatin active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Carboplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-491-2015·2015-04-29
Attix Pharmaceuticals Recalls 5-Aminolevulinic Acid Hydrochloride Due to Penicillin Cross-Contamination
Attix Pharmaceuticals is recalling 5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-870-2015·2015-04-29
Attix Pharmaceuticals Recalls Proparacaine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Proparacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Proparacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide

How to read this listing

Filters

9176–9200 of 11823